GMOV - ETF AI Analysis
Top Page
GMO US Value ETF (GMOV)
Rating:73Outperform
Price Target:―
Positive Factors
Solid Recent Performance Trend
The ETF has shown steady gains over the last three months, indicating improving momentum in its value-focused strategy.
Diversified Sector Mix
Holdings are spread across financials, health care, communication services, consumer sectors, energy, and technology, which helps reduce reliance on any single industry.
Strong Core Holdings
Several of the largest positions, such as Exxon Mobil, Chevron, Johnson & Johnson, and Merck, have delivered strong year-to-date results that support the fund’s overall performance.
Negative Factors
Moderately High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can gradually eat into long-term returns compared with lower-cost alternatives.
Concentrated U.S. Exposure
With almost all assets invested in U.S. companies, the ETF offers little geographic diversification and is heavily tied to the U.S. market’s fortunes.
Mixed Performance Among Top Holdings
Some major positions, including Meta Platforms, Bank of America, and Verizon, have shown weak year-to-date performance, which can drag on the fund if this trend continues.
GMOV vs. SPDR S&P 500 ETF (SPY)
AUM78.57M
RegionNorth America
Expense Ratio0.50%
Beta0.79
IssuerGMO
Inception DateOct 28, 2024
Dividend Yield1.93%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume15,294
30 Day Avg. Volume17,553
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
32.76Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering166
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GMOV Summary
GMOV is the GMO US Value ETF, which invests in a wide range of U.S. stocks with a focus on companies that appear cheap compared with their business strength. It doesn’t track a set index, but follows a value theme across the total U.S. market, with big positions in well-known names like Exxon Mobil and Johnson & Johnson. Investors might consider GMOV if they want diversified exposure to U.S. stocks while tilting toward value companies that could have room to grow. A key risk is that value stocks can lag the overall market for long periods and the share price can go up and down with market swings.
How much will it cost me?The GMO US Value ETF (GMOV) has an expense ratio of 0.5%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because the fund is actively managed, relying on expert analysts to select undervalued stocks with strong growth potential.
What would affect this ETF?The GMO US Value ETF could benefit from a favorable economic environment that supports undervalued stocks, particularly in sectors like Financials and Health Care, which are heavily represented in its portfolio. However, rising interest rates or regulatory changes in key sectors such as Technology and Energy could negatively impact the ETF's performance. Additionally, shifts in consumer spending or market sentiment might influence the value of top holdings like Johnson & Johnson and Meta Platforms.
GMOV Top 10 Holdings
GMOV leans heavily into classic U.S. value territory, with big weights in financials, health care, and energy. Exxon Mobil and Chevron are doing much of the heavy lifting as energy stays in favor, while Verizon’s rebound adds extra fuel from the communications side. In health care, Johnson & Johnson and Merck are quietly powering ahead, giving the fund a steady defensive backbone. Alphabet is more of a mixed story, recently losing a bit of steam, which slightly offsets gains elsewhere. Overall, it’s a U.S.-only, value-first lineup with no single stock dominating the show.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Exxon Mobil | 4.08% | $3.41M | $661.72B | 39.75% | 74 Outperform | |
| Johnson & Johnson | 3.70% | $3.09M | $573.82B | 48.06% | 78 Outperform | |
| Meta Platforms | 2.85% | $2.39M | $1.58T | 6.92% | 76 Outperform | |
| Merck & Company | 2.85% | $2.39M | $286.48B | 21.77% | 80 Outperform | |
| Alphabet Class A | 2.82% | $2.36M | $3.75T | 93.51% | 85 Outperform | |
| Verizon | 2.65% | $2.22M | $213.08B | 15.24% | 81 Outperform | |
| Chevron | 2.50% | $2.10M | $395.03B | 23.11% | 71 Outperform | |
| Pfizer | 2.15% | $1.80M | $156.09B | 1.14% | 74 Outperform | |
| Bank of America | 2.12% | $1.77M | $339.31B | 13.52% | 72 Outperform | |
| Procter & Gamble | 2.06% | $1.73M | $352.04B | -9.30% | 69 Neutral |
GMOV Technical Analysis
Neutral
―
Price Trends
28.62
Negative
27.71
Positive
26.56
Positive
Market Momentum
-0.20
Positive
39.33
Neutral
15.34
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GMOV, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 28.77, equal to the 50-day MA of 28.62, and equal to the 200-day MA of 26.56, indicating a neutral trend. The MACD of -0.20 indicates Positive momentum. The RSI at 39.33 is Neutral, neither overbought nor oversold. The STOCH value of 15.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GMOV.
GMOV Peer Comparison
Comparison Results
Performance Comparison
GMOV
GMO US Value ETF
28.20
3.98
16.43%
BAMV
Brookstone Value Stock ETF
―
―
―
TCV
Towle Value ETF
―
―
―
VUSV
Vanguard Wellington U.S. Value Active ETF
―
―
―
GVLE
Goldman Sachs Value Opportunities ETF
―
―
―
CVAR
Cultivar ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents